

wherein: A is

(i) $(\text{CH}_2)_n\text{-N-C(O)O-C}_{1-6}$ alkyl; and W is C_{1-6} alkyl; or
W

(ii) $(\text{CH}_2)_2\text{-N-}$ and forms a six membered ring
Y

with B, said ring containing one nitrogen;

Y is

(a) C_{1-6} alkyl, or H;

(b) C(O)-C_{1-6} alkyl;

(c) $\text{CH}_2\text{CH}(\text{OH})\text{-CH}_2\text{-Z}$, wherein Z is C_{1-6} alkyl or O-C_{1-6} alkyl;

(d) aryl; or

(e) heterocycle;

B is a single bond, OH or halo;

C is -OH, $-\text{CH}_2-$ or forms a 5-membered lactone or lactam ring with D; and

D is:
 (i) -OH, -CH₂-halo, -CH(O)-, -COOH, -C(O)-O-C₁₋₆ alkyl, -(CH₂)_n-,
 -CHOH-, wherein n is an integer and is 1,2, or 3; or


 (ii) forms a 5-membered lactone or lactam ring with C;

 E is -H or -CH₃; and

 F is -OH,

or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, said
composition useful in the treatment of neoplastic diseases,

with the proviso that the formula excludes noscapine of the structure



and a pharmaceutically acceptable carrier therefor.